Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.
A blood test analyzing tumor DNA's cellular packaging patterns predicts which rare leiomyosarcoma patients will respond to immunotherapy, addressing a critical treatment gap.
A novel liquid biopsy platform using cfDNA active chromatin profiling identified baseline epigenomic signatures predictive of immunotherapy benefit in 30 leiomyosarcoma patients, with B/T-cell activation and immune pathway enrichment correlating with progression-free survival. This proof-of-concept approach represents a potentially high-value non-invasive biomarker for a rare, chemotherapy-resistant cancer that desperately needs treatment predictors.
What the study was
- Study design
- Exploratory biomarker analysis (prospective clinical trial subset)
- Population
- Leiomyosarcoma patients treated with durvalumab + olaparib or cediranib
- Sample size
- 30
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- npj Precision Oncology
Why it surfaced
Highly novel cfDNAac approach in npj Precision Oncology (Nature group); LMS is rare with no reliable immunotherapy predictors; N=30 is exploratory but signal is clear; multi-conflict authors suggest commercial interest in Aqtual platform.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.